Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) have been assigned an average recommendation of “Buy” from the eight brokerages that are currently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $21.57.
A number of analysts recently commented on the stock. Guggenheim assumed coverage on shares of Zevra Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $20.00 target price on the stock. Canaccord Genuity Group cut their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Cantor Fitzgerald began coverage on Zevra Therapeutics in a report on Wednesday, January 8th. They issued an “overweight” rating and a $25.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Wednesday, November 20th.
Get Our Latest Analysis on Zevra Therapeutics
Zevra Therapeutics Stock Performance
Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. During the same period in the prior year, the business earned ($0.40) EPS. Research analysts predict that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.
Institutional Investors Weigh In On Zevra Therapeutics
A number of institutional investors have recently bought and sold shares of ZVRA. Rhumbline Advisers lifted its position in shares of Zevra Therapeutics by 17.9% in the second quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock worth $279,000 after purchasing an additional 8,619 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after buying an additional 2,452 shares during the period. Sanctuary Advisors LLC purchased a new position in shares of Zevra Therapeutics during the 2nd quarter valued at $474,000. SG Americas Securities LLC purchased a new position in shares of Zevra Therapeutics during the 3rd quarter valued at $105,000. Finally, City State Bank increased its stake in shares of Zevra Therapeutics by 14.1% in the third quarter. City State Bank now owns 16,224 shares of the company’s stock worth $113,000 after acquiring an additional 2,000 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.
About Zevra Therapeutics
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
Featured Stories
- Five stocks we like better than Zevra Therapeutics
- Insider Trades May Not Tell You What You Think
- Sizing Up a New Opportunity for NVIDIA Investors
- Using the MarketBeat Dividend Yield Calculator
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- What is Insider Trading? What You Can Learn from Insider Trading
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.